Xanthine oxidase inhibition for chronic heart failure: Is allopurinol the next therapeutic advance in heart failure?

Heart

Volumn 91, Issue 6, 2005, Pages 707-709

  Doehner, Wolfram ^a   Anker, S D ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; REACTIVE OXYGEN METABOLITE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; ENZYME METABOLISM; EXERCISE; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERURICEMIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ALLOPURINOL; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; ENZYME INHIBITORS; EXERCISE TOLERANCE; HUMANS; OXYGEN CONSUMPTION; XANTHINE OXIDASE;

EID: 20044363683     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.057190     Document Type: Editorial

References (32)

1. Gimpel JA, Lahpor JR, van der Molen AJ, et al. Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med 1995;19:251-5.
2. Coghlan JG, Flitter WD, Clutton SM, et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;107:248-56.
3. Guan W, Osanai T, Kamada T, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 2003;41:699-705.
4. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not after exercise capacity in chronic heart failure. Heart 2005;91:749-53.
5. Bakhtiiarov, ZA [Changes in xanrhine oxidase activity in patients with circulatory failure.] Ter Arkh 1989;61:68-9.
6. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11.
7. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-8.
8. Doehner W, Rauchhaus M, Florea VG, et al. Uric acid in cachectic and non-cachectic CHF patients-relation to leg vascular resistance. Am Heart J 2001;141:792-9.
9. Leyva F, Anker SD, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65.
10. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
11. Doehner W, Schoene N, Rauchhaus M, et al. The effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure-results from two placebo controlled studies. Circulation 2002;105:2619-24.
12. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-6.
13. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94:932-5.
14. Ukai T, Cheng CP, Tachibana H, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001;103:750-5.
15. Perez NG, Gao WD, Marban E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 1998;83:423-30.
16. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-45.
17. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004;110:2175-9.
18. Bolger AP, Al-Nasser F. Beta-blockers for chronic heart failure: surviving longer but feeling better? Int J Cardiol 2003;92:1-8.
19. Hambrecht R. [Physical exercise as treatment strategy] Herz 2004;29:381-90.
20. McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the exercise rehabilitation trial (EXERT). Am Heart J 2002;144:23-30.
21. Mancini D, LeJemtel T, Aaronson K. Peak VO (2): a simple yet enduring standard. Circulation 2000;101:1080-2.
22. Sarnesto A, Linder N, Raivio KO. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest 1996;74:48-56.
23. Jarasch ED, Grund C, Bruder G, et al. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981;25:67-82.
24. Tubaro E, Lotti B, Cavallo G, et al. Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism. Biochem Pharmacol 1980;29:1939-43.
25. Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000;60:1245-57.
26. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999;33:959-65.
27. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210-14.
28. Freudenberger RS, Schwarz RP Jr, Brown J, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs 2004;13:1509-16.
29. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21.
30. Netea MG, Kullberg BJ, Blok WL, et al. The role of hyperuricemia in the increased cytokine production after lipopolysacchariae challenge in neutropenic mice. Blood 1997;89:577-82.
31. Bagnati M, Perugini C, Cau C, et al. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999;340:143-52.
32. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8.